From Nuclear Winter to Renewal: Biotech Investing for 2026

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top